JP2009511450A5 - - Google Patents

Download PDF

Info

Publication number
JP2009511450A5
JP2009511450A5 JP2008534023A JP2008534023A JP2009511450A5 JP 2009511450 A5 JP2009511450 A5 JP 2009511450A5 JP 2008534023 A JP2008534023 A JP 2008534023A JP 2008534023 A JP2008534023 A JP 2008534023A JP 2009511450 A5 JP2009511450 A5 JP 2009511450A5
Authority
JP
Japan
Prior art keywords
leukemia
methyl
formula
pharmaceutical combination
disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2008534023A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009511450A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2006/067117 external-priority patent/WO2007042465A2/en
Publication of JP2009511450A publication Critical patent/JP2009511450A/ja
Publication of JP2009511450A5 publication Critical patent/JP2009511450A5/ja
Pending legal-status Critical Current

Links

JP2008534023A 2005-10-07 2006-10-05 ニロチニブとファルネシルトランスフェラーゼ阻害剤の組合せ Pending JP2009511450A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US72459405P 2005-10-07 2005-10-07
PCT/EP2006/067117 WO2007042465A2 (en) 2005-10-07 2006-10-05 Combinati0n of nilotinib with farnesyl transferase inhibitors

Publications (2)

Publication Number Publication Date
JP2009511450A JP2009511450A (ja) 2009-03-19
JP2009511450A5 true JP2009511450A5 (enExample) 2009-09-17

Family

ID=37943163

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2008534023A Pending JP2009511450A (ja) 2005-10-07 2006-10-05 ニロチニブとファルネシルトランスフェラーゼ阻害剤の組合せ

Country Status (3)

Country Link
US (1) US20080255171A1 (enExample)
JP (1) JP2009511450A (enExample)
WO (1) WO2007042465A2 (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102861338A (zh) * 2006-04-05 2013-01-09 诺瓦提斯公司 用于治疗癌症、包含bcr-abl/c-kit/pdgf-r tk抑制剂的组合
US8232402B2 (en) 2008-03-12 2012-07-31 Link Medicine Corporation Quinolinone farnesyl transferase inhibitors for the treatment of synucleinopathies and other indications
US20100160372A1 (en) * 2008-11-13 2010-06-24 Link Medicine Corporation Treatment of proteinopathies using a farnesyl transferase inhibitor
CA2743717A1 (en) 2008-11-13 2010-05-20 Link Medicine Corporation Azaquinolinone derivatives and uses thereof
BR112017011972A2 (pt) * 2014-12-18 2017-12-26 Novartis Ag derivados de azabicicloctano como agonistas de fxr para uso no tratamento de doenças hepáticas e gastrintestinais
WO2024229406A1 (en) 2023-05-04 2024-11-07 Revolution Medicines, Inc. Combination therapy for a ras related disease or disorder
US20250049810A1 (en) 2023-08-07 2025-02-13 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
TW202530228A (zh) 2023-10-12 2025-08-01 美商銳新醫藥公司 Ｒａｓ抑制劑
WO2025171296A1 (en) 2024-02-09 2025-08-14 Revolution Medicines, Inc. Ras inhibitors
TW202547461A (zh) 2024-05-17 2025-12-16 美商銳新醫藥公司 Ｒａｓ抑制劑
WO2025255438A1 (en) 2024-06-07 2025-12-11 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2025265060A1 (en) 2024-06-21 2025-12-26 Revolution Medicines, Inc. Therapeutic compositions and methods for managing treatment-related effects
WO2026006747A1 (en) 2024-06-28 2026-01-02 Revolution Medicines, Inc. Ras inhibitors
WO2026015790A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015801A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015796A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015825A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Use of ras inhibitor for treating pancreatic cancer
WO2026050446A1 (en) 2024-08-29 2026-03-05 Revolution Medicines, Inc. Ras inhibitors

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002028381A2 (en) * 2000-10-05 2002-04-11 Daley George Q Methods of inducing cancer cell death and tumor regression
AU2002211427A1 (en) * 2000-10-05 2002-04-15 Whitehead Institute For Biomedical Research Effects of combined administration of farnesyl transferase inhibitors and signal transduction inhibitors
CN1617755A (zh) * 2001-11-30 2005-05-18 先灵公司 法尼基蛋白转移酶抑制剂和其它抗肿瘤剂联合使用在制备抗癌症的药物中的应用
GB0215676D0 (en) * 2002-07-05 2002-08-14 Novartis Ag Organic compounds

Similar Documents

Publication Publication Date Title
JP2009511450A5 (enExample)
JP2013531028A5 (enExample)
JP2009532438A5 (enExample)
JP2015508749A5 (enExample)
JP2017528507A5 (enExample)
JP2013523733A5 (enExample)
JP2017505293A5 (enExample)
JP2010515715A5 (enExample)
JP2014502641A5 (enExample)
JP2017530983A5 (enExample)
JP2020512337A5 (enExample)
CN111902417A (zh) 一种二芳基巨环化合物、药物组合物以及其用途
RU2008143703A (ru) ПРИМЕНЕНИЕ ИНГИБИТОРОВ c-Src В КОМБИНАЦИИ С ПИРИМИДИЛАМИНОБЕНЗАМИДОМ ДЛЯ ЛЕЧЕНИЯ ЛЕЙКОЗА
JP2009511568A5 (enExample)
NZ590839A (en) Treatment of pulmonary arterial hypertension
JP2012507535A5 (enExample)
JPWO2020175629A5 (enExample)
JP2013506674A5 (enExample)
JP2008536853A5 (enExample)
JP2008519049A5 (enExample)
JP2020500868A5 (enExample)
JP2019501134A5 (enExample)
JP2013544794A5 (enExample)
JP2021522246A (ja) 癌治療のための併用
JP2014534229A5 (enExample)